On the 13th, Tegosience's stock price is on the rise. The company announced that it has submitted a clinical phase 1 trial plan for the allogeneic skin cell therapy product ‘TPX-121’ for improving lip wrinkles to the Ministry of Food and Drug Safety, which is interpreted as attracting buying interest due to expectations.
As of 11:18 AM on the same day, Tegosience's stock price is trading at 10,620 KRW, up 3.71% compared to the previous trading day. It rose to 11,050 KRW in the early session.
TPX-121 is an allogeneic fibroblast therapy product for wrinkle improvement that addresses the drawbacks such as skin harvesting and culturing periods of the autologous cell therapy product ‘Rosmir’ currently on the market. TPX-121 is Tegosience's third allogeneic cell therapy product following its main products: the burn and foot ulcer treatment ‘Caloderm’ and the rotator cuff tear treatment ‘TPX-115’, which is undergoing clinical phase 2b/3 trials.
Tegosience is targeting the domestic facial beauty market worth approximately 400 billion KRW annually and the global market valued at 13 trillion KRW, challenging the development of the world's first allogeneic cell therapy for facial wrinkle improvement.
A Tegosience representative stated, “TPX-121 has completed preclinical studies and the establishment of a cell bank, enabling us to apply for clinical phase 1 trials,” and added, “We will devote all efforts to developing the world’s first injectable allogeneic cell therapy for facial wrinkle improvement.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
